Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company’s New Sham Tip for Pivotal PURSUIT Trial Aug 25, 2020
Viveve to Host Conference Call on August 13, 2020 to Report Second Quarter 2020 Financial Results and Provide Corporate Update Aug 6, 2020
Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence Jul 7, 2020
